CTKB
Cytek Biosciences, Inc.
+0.21 (+4.16%)5.14USD1.2M成交股數667M市值–本益比(近四季)3.2股價營收比+5.6%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 48.1M+16% | 44.1M | 52.3M+2% | 45.6M-2% | 41.5M-8% | – | 51.5M+7% | 46.6M-6% | 44.9M | – | 48.0M | 49.7M |
| 營業成本 | 19.8M | 22.9M | 24.7M | 21.7M | 21.3M | – | 22.5M | 21.2M | 21.8M | – | 20.8M | 21.5M |
| 毛利 | 28.3M+41% | 21.3M | 27.6M-5% | 23.9M-6% | 20.2M-12% | – | 29.0M+7% | 25.4M-10% | 23.0M | – | 27.2M | 28.2M |
| 毛利率 | 58.9% | 48.2% | 52.7% | 52.3% | 48.6% | – | 56.3% | 54.6% | 51.3% | – | 56.6% | 56.7% |
| 研發費用 | 9.7M | 9.6M | 9.0M | 8.8M | 9.7M | – | 9.9M | 10.0M | 9.8M | – | 11.2M | 12.1M |
| 銷售管理費用 | 16.8M | 18.5M | 16.1M | 13.5M | 12.9M | – | 10.9M | 11.7M | 11.4M | – | 10.4M | 10.8M |
| 營業利益 | −11.4M-24% | −18.5M | −9.2M+116% | −10.6M+25% | −15.0M+40% | – | −4.2M-34% | −8.5M-7% | −10.7M | – | −6.4M | −9.1M |
| 營業利益率 | -23.7% | -41.8% | -17.6% | -23.3% | -36.1% | – | -8.2% | -18.3% | -23.9% | – | -13.4% | -18.4% |
| 稅後淨利 | −12.2M+7% | −18.9M | −5.5M-682% | −5.6M-46% | −11.4M+85% | – | 941K-115% | −10.4M+138% | −6.2M | – | −6.5M | −4.4M |
| 淨利率 | -25.3% | -42.7% | -10.5% | -12.2% | -27.5% | – | 1.8% | -22.4% | -13.8% | – | -13.5% | -8.8% |
| 稀釋 EPS | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋股數 | 129M | 129M | 128M | 127M | 128M | – | 133M | 131M | 131M | – | 136M | 136M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 73.8M | 65.7M | 93.3M | 75.5M | 95.3M | 98.7M | 162M | 178M | 169M | 167M | 164M | 132M |
| 應收帳款 | 49.7M | 51.9M | 56.6M | 56.2M | 55.0M | 60.6M | 52.6M | 44.6M | 50.3M | 55.9M | 55.4M | 49.6M |
| 存貨 | 52.3M | 49.8M | 51.6M | 49.5M | 45.3M | 43.9M | 46.8M | 50.1M | 54.7M | 60.9M | 66.9M | 65.7M |
| 總資產 | 447M | 449M | 495M | 493M | 483M | 500M | 491M | 484M | 492M | 494M | 519M | 525M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 125M | 121M | 116M | 116M | 103M | 104M | 106M | 94.6M | 99.5M | 101M | 104M | 101M |
| 股東權益 | 322M | 328M | 379M | 378M | 380M | 396M | 385M | 389M | 393M | 393M | 416M | 424M |
| 負債比 | 28.0% | 27.0% | 23.5% | 23.5% | 21.3% | 20.8% | 21.5% | 19.6% | 20.2% | 20.5% | 20.0% | 19.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.7M | – | – | −125K-103% | – | – | – | 4.0M | – | – | – |
| 資本支出 | – | 2.2M | – | – | 849K | – | – | – | 567K | – | – | – |
| 自由現金流 | – | −4.9M | – | – | −974K-129% | – | – | – | 3.4M | – | – | – |
| 折舊攤銷 | – | 1.9M | – | – | 1.9M | – | – | – | 1.7M | – | – | – |
| 買回庫藏股 | – | 0.00 | – | – | 10.6M | 7.0M | 11.9M | 2.7M | 0.00 | 34.6M | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -11.1% | – | – | -2.3% | – | – | – | 7.6% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 201M
| Reportable | 201M | 100.0% | +0.5% |
|---|
地區2025 年度 · 222M
| 美國 | 95.3M | 42.9% | +2.9% |
|---|---|---|---|
| 歐洲中東非洲 | 55.9M | 25.2% | -10.4% |
| 亞太 | 41.1M | 18.5% | +14.8% |
| 中國 | 20.5M | 9.2% | – |
| 其他 | 9.3M | 4.2% | -4.6% |
主要客戶2025 年度 · 201M
| Biotechnology Pharmaceutical Distributor And CRO | 117M | 57.9% | -2.4% |
|---|---|---|---|
| Academia And Government | 84.8M | 42.1% | +4.8% |
產品／服務2025 年度 · 201M
| 產品 | 144M | 71.6% | -5.9% |
|---|---|---|---|
| 服務 | 57.3M | 28.4% | +21.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 201M | +0.5% | −66.5M | -33.0% | – | −8.8M |
| FY2024 | 200M | +3.9% | −6.0M | -3.0% | – | 21.9M |
| FY2023 | 193M | +17.7% | −12.1M | -6.3% | -0.09 | 633K |
| FY2022 | 164M | +28.2% | 2.5M | 1.5% | 0.02 | −22.0M |
| FY2021 | 128M | +37.8% | 3.0M | 2.4% | 0.00 | 266K |
| FY2020 | 92.8M | – | 19.4M | 20.9% | 0.10 | 13.6M |